Lejeune A, Poyet P, Gaudreault R C, Gicquaud C
Département de Chimie-Biologie, Université du Québec à Trois-Rivières, Canada.
Anticancer Res. 1997 Sep-Oct;17(5A):3599-603.
We have previously developed a new drug carrier, named nanoerythrosome which is prepared by extrusion of erythrocyte ghosts to produce small vesicles having an average diameter of 100 nm. Daunorubicin (DNR) conjugated to these nanoerythrosomes has a higher antineoplastic index than the free drug. Moreover, since nanoerythrosomes are particles, phagocytosis may be involved in their mechanism of potentiation. In the present study, we have compared the mechanism of penetration between free DNR and conjugate DNR linked to nanoerythrosomes, on cells presenting high phagocytic activity, macrophages, and cells lacking phagocytic activity, the P388 D1 cell line. Our results demonstrate that: 1) The nanoerythrosome-DNR complex is rapidly adsorbed and phagocytosed by the macrophages, but not by the P388 D1 cell line. 2) On the contrary, DNR enters both phagocytic and non phagocytic cells. Furthermore, the cellular distribution of DNR is the same in both cell lines, the nucleus being the target organelle. We conclude that phagocytosis of the nanoerythrosome-DNR complex is not involved in its mechanism of action.
我们之前研发了一种名为纳米红细胞体的新型药物载体,它是通过挤压红细胞膜制备而成的,平均直径为100纳米的小囊泡。与这些纳米红细胞体结合的柔红霉素(DNR)比游离药物具有更高的抗肿瘤指数。此外,由于纳米红细胞体是颗粒,吞噬作用可能参与其增效机制。在本研究中,我们比较了游离DNR和与纳米红细胞体相连的结合型DNR在具有高吞噬活性的细胞(巨噬细胞)和缺乏吞噬活性的细胞(P388 D1细胞系)中的渗透机制。我们的结果表明:1)纳米红细胞体-DNR复合物被巨噬细胞快速吸附和吞噬,但不被P388 D1细胞系吞噬。2)相反,DNR进入吞噬细胞和非吞噬细胞。此外,DNR在两种细胞系中的细胞分布相同,细胞核是靶细胞器。我们得出结论,纳米红细胞体-DNR复合物的吞噬作用不参与其作用机制。